Andrew Mallett1, Wen Tang2, Philip A Clayton3, Sarah Stevenson4, Stephen P McDonald5, Carmel M Hawley4, Sunil V Badve4, Neil Boudville6, Fiona G Brown7, Scott B Campbell4, David W Johnson4. 1. ANZDATA Registry, Adelaide, South Australia, Australia Department of Nephrology, Princess Alexandra Hospital, Brisbane, Queensland, Australia Department of Renal Medicine, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia. 2. Division of Nephrology, Peking University Third Hospital, Beijing, China. 3. ANZDATA Registry, Adelaide, South Australia, Australia Department of Renal Medicine, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia School of Public Health, University of Sydney, Sydney, New South Wales, Australia. 4. ANZDATA Registry, Adelaide, South Australia, Australia Department of Nephrology, Princess Alexandra Hospital, Brisbane, Queensland, Australia. 5. ANZDATA Registry, Adelaide, South Australia, Australia Department of Nephrology and Transplantation Services, University of Adelaide at Central Northern Adelaide Renal and Transplantation Services, Adelaide, South Australia, Australia. 6. ANZDATA Registry, Adelaide, South Australia, Australia School of Medicine and Pharmacology, Sir Charles Gairdner Hospital Unit, The University of Western Australia, Perth, Western Australia, Australia. 7. ANZDATA Registry, Adelaide, South Australia, Australia Department of Nephrology, Monash Medical Centre, Melbourne, Victoria, Australia.
Abstract
BACKGROUND: Alport syndrome is a rare inheritable renal disease. Clinical outcomes for patients progressing to end-stage kidney disease (ESKD) are not well described. METHODS: This study aimed to investigate the characteristics and clinical outcomes of patients from Australia and New Zealand commencing renal replacement therapy (RRT) for ESKD due to Alport syndrome between 1965 and 1995 (early cohort) and between 1996 and 2010 (contemporary cohort) compared with propensity score-matched, RRT-treated, non-Alport ESKD controls. RESULTS: A total of 58 422 patients started RRT during this period of which 296 (0.5%) patients had Alport ESKD. In the early cohort, Alport ESKD was associated with superior dialysis patient survival [adjusted hazard ratio (HR): 0.41, 95% confidence interval (CI): 0.20-0.83, P = 0.01], renal allograft survival (HR: 0.74, 95% CI: 0.54-1.01, P = 0.05) and renal transplant patient survival (HR: 0.43, 95% CI: 0.28-0.66, P < 0.001) compared with controls. In the contemporary cohort, no differences were observed between the two groups for dialysis patient survival (HR: 1.42, 95% CI: 0.65-3.11, P = 0.38), renal allograft survival (HR: 1.01, 95% CI: 0.57-1.79, P = 0.98) or renal transplant patient survival (HR: 0.67, 95% CI: 0.26-1.73, P = 0.41). One Alport patient (0.4%) had post-transplant anti-glomerular basement membrane (anti-GBM) disease. Four female and 41 male Alport patients became parents on RRT with generally good neonatal outcomes. CONCLUSION: Alport syndrome patients experienced comparable dialysis and renal transplant outcomes to matched non-Alport ESKD controls in the contemporary cohort due to relatively greater improvements in outcomes for non-Alport ESKD patients over time. Post-transplant anti-GBM disease was rare.
BACKGROUND:Alport syndrome is a rare inheritable renal disease. Clinical outcomes for patients progressing to end-stage kidney disease (ESKD) are not well described. METHODS: This study aimed to investigate the characteristics and clinical outcomes of patients from Australia and New Zealand commencing renal replacement therapy (RRT) for ESKD due to Alport syndrome between 1965 and 1995 (early cohort) and between 1996 and 2010 (contemporary cohort) compared with propensity score-matched, RRT-treated, non-Alport ESKD controls. RESULTS: A total of 58 422 patients started RRT during this period of which 296 (0.5%) patients had Alport ESKD. In the early cohort, Alport ESKD was associated with superior dialysis patient survival [adjusted hazard ratio (HR): 0.41, 95% confidence interval (CI): 0.20-0.83, P = 0.01], renal allograft survival (HR: 0.74, 95% CI: 0.54-1.01, P = 0.05) and renal transplant patient survival (HR: 0.43, 95% CI: 0.28-0.66, P < 0.001) compared with controls. In the contemporary cohort, no differences were observed between the two groups for dialysis patient survival (HR: 1.42, 95% CI: 0.65-3.11, P = 0.38), renal allograft survival (HR: 1.01, 95% CI: 0.57-1.79, P = 0.98) or renal transplant patient survival (HR: 0.67, 95% CI: 0.26-1.73, P = 0.41). One Alport patient (0.4%) had post-transplant anti-glomerular basement membrane (anti-GBM) disease. Four female and 41 male Alport patients became parents on RRT with generally good neonatal outcomes. CONCLUSION:Alport syndromepatients experienced comparable dialysis and renal transplant outcomes to matched non-Alport ESKD controls in the contemporary cohort due to relatively greater improvements in outcomes for non-Alport ESKD patients over time. Post-transplant anti-GBM disease was rare.
Authors: Michelle M O'Shaughnessy; Maria E Montez-Rath; Richard A Lafayette; Wolfgang C Winkelmayer Journal: Clin J Am Soc Nephrol Date: 2015-06-19 Impact factor: 8.237
Authors: Valentine Gillion; Karin Dahan; Jean-Pierre Cosyns; Pascale Hilbert; Michel Jadoul; Eric Goffin; Nathalie Godefroid; Martine De Meyer; Michel Mourad; Yves Pirson; Nada Kanaan Journal: Kidney Int Rep Date: 2018-02-02
Authors: Yvelynne P Kelly; Anish Patil; Luke Wallis; Susan Murray; Saumitra Kant; Mohammed A Kaballo; Liam Casserly; Brendan Doyle; Anthony Dorman; Patrick O'Kelly; Peter J Conlon Journal: Ren Fail Date: 2016-12-05 Impact factor: 2.606
Authors: Raquel Martínez-Pulleiro; María García-Murias; Manuel Fidalgo-Díaz; Miguel Ángel García-González Journal: Int J Mol Sci Date: 2021-10-14 Impact factor: 5.923
Authors: Oliver Gross; Clifford E Kashtan; Michelle N Rheault; Frances Flinter; Judith Savige; Jeffrey H Miner; Roser Torra; Elisabet Ars; Constantinos Deltas; Isavella Savva; Laura Perin; Alessandra Renieri; Francesca Ariani; Francesca Mari; Colin Baigent; Parminder Judge; Bertrand Knebelman; Laurence Heidet; Sharon Lagas; Dave Blatt; Jie Ding; Yanqin Zhang; Daniel P Gale; Marco Prunotto; Yong Xue; Asher D Schachter; Lori C G Morton; Jacqui Blem; Michael Huang; Shiguang Liu; Sebastien Vallee; Daniel Renault; Julia Schifter; Jules Skelding; Susie Gear; Tim Friede; A Neil Turner; Rachel Lennon Journal: Nephrol Dial Transplant Date: 2017-06-01 Impact factor: 5.992